Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 11/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 11/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 11/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32671633 | 0.79 | PTPN11 (0.60) | RBP4MEN1KMT2APTPN11POLB | |
| SCHEMBL2972417 | 0.78 | RBP4 (0.41) | RBP4PTPN11POLBSMN1; SMN2ADRA2A | |
| SCHEMBL2979002 | 0.77 | HDAC1 (0.43) | MEN1KMT2AMTHFD2HDAC1 | |
| SCHEMBL2981055 | 0.76 | HDAC1 (0.55) | HDAC1 | |
| SCHEMBL2978283 | 0.70 | MPL (0.41) | RBP4POLBSMN1; SMN2 | |
| SCHEMBL32671622 | 0.69 | POLB (0.75) | PTPN11POLBSMN1; SMN2 | |
| SCHEMBL2979164 | 0.69 | BAZ2B (0.54) | MEN1KMT2ASMN1; SMN2HDAC1 | |
| SCHEMBL1013949 | 0.69 | POLB (0.59) | RBP4KMT2APTPN11POLBSMN1; SMN2 | |
| SCHEMBL5507692 | 0.69 | MTHFD2 (0.52) | MEN1KMT2ASMN1; SMN2MTHFD2HDAC1 | |
| SCHEMBL30331571 | 0.68 | POLB (0.78) | PTPN11POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199829-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | RBP4 4150/4885MEN1 3925/4885KMT2A 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.